
The search for alternatives to antibiotic growth promoters (AGPs) has been underway for decades. Organic acids, fatty acids, phytogenic compounds and microbial preparations have been explored for their potential to support gut health and animal performance. Yet consistent, sustainable performance under commercial conditions remains a challenge. For feed manufacturers, livestock producers and distributors, choosing the right solution is rarely straightforward. Products differ in their intended functions, supporting evidence, inclusion rates and costs, while results depend on diet, animal health, disease pressure, environment and management. What matters is finding a solution that addresses the actual problem and delivers lasting value.
1. Different Challenges, Different Approaches
Intestinal challenges do not share a single cause. Undesirable microorganisms may increase intestinal microbial pressure, while toxins, mucosal damage, excessive inflammation and pathological fluid secretion can impair intestinal function and nutrient utilization. Antimicrobial approaches aim to control undesirable microorganisms. Non-antimicrobial approaches address intestinal dysfunction through toxin neutralization, intestinal astringency and mucosal protection, inflammation modulation or anti-secretory regulation. Understanding the underlying challenge is essential to selecting an appropriate intervention.
Evidence must also match the intended function. For antimicrobial candidates, minimum inhibitory concentration (MIC) testing provides a quantitative comparison of activity against relevant pathogens. For other candidates, assessment should focus on their specific functional effects. Such screening helps identify promising solutions before investing in extensive animal studies.
2. From Laboratory Activity to Animal Efficacy
Strong laboratory activity does not automatically translate into animal efficacy. Digestion, absorption and interactions with intestinal contents may limit the amount of an active compound reaching its intended site. For suitable compounds, targeted delivery technologies can help control intestinal release and improve local availability. Whether these advantages translate into animal health and performance benefits must still be verified.
For products developed to address specific intestinal challenges, controlled challenge studies directly assess efficacy under defined disease pressure. They establish whether a solution can effectively address the targeted challenge, using outcomes such as diarrhea incidence, intestinal lesions or challenge-related performance losses. This provides direct evidence of its intended function.
3. From Controlled Studies to Commercial Value
Controlled animal trials with research institutions worldwide further assess performance consistency and practical relevance. Commercial trials examine whether benefits remain reproducible across diets, environments and management systems, and whether improvements justify supplementation costs.
This progression—from in vitro screening and controlled challenge studies to research collaborations and large-scale commercial validation—forms part of Insighter Biotechnology’s approach to gut health solutions. Its focus is reliable performance and meaningful economic value under practical production conditions.
At EuroTier 2026, Insighter welcomes feed manufacturers, livestock producers and distribution partners to discuss their intestinal health challenges and explore science-driven solutions for their production goals. Our next article will introduce Insighter’s antimicrobial and non-antimicrobial technologies.
EuroTier 2026 | November 10–13 | Hannover, Germany
Hall 21 · Stand G23
www.insighterbt.com




